Skip to main content

Table 2 Patient data at baseline and after 6 months study period

From: Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure

 

Baseline

After 6 months

N

56

46

Dropped out

N/A

10

BMI (kg/m2)

25.07

24.82

Blood pressure (SBP/DBP)(mmHg)

138 (9.67)/78.6 (11.5)

129.5 (10.62)/73.1 (12.0)*

Duration (y)

15.47 (10.67)

16.54 (10.88)

Laboratory data

HbA1c (%)

6.87 (0.68)

6.86 (0.93)

FPG (mg/dl)

151.7 (47.5)

137.02 (55.22)

HWM-AND (μg/ml)

4.89 (3.16)

5.87 (3.90)*

PAI-1 (mg/dl)

27.63 (16.28)

23.17 (7.43)*

VCAM-1 (mg/dl)

715.09 (173.70)

712.06 (196.04)

U-8-OHdG (pg/ml)

11.28 (3.22)

11.65 (3.15)

Hs-CRP (mg/dl)

0.093171 (0.015391)

0.099737 (0.015174)

Blood glucose lowering treatment

Insulin only

11

10

Insulin+OHA

7

7

OHA

32

24

Diet only

6

5

  1. BMI, body mass index; HbA1c, glycated hemoglobin A1c; FPG, fasting plasma glucose; HMW-ADN, high molecular weight-adiponectin; PAI-1, plasminogen activator inhibitor-1; VCAM-1, vascular cell adhesion molecule-1; U-8-OHdG, urinary-8-hydroxydeoxyguanosine; Hs-CRP, high-sensitivity C-reactive protein; OHA, oral hypoglycemic agent. Data are expressed as means±s.d. or n and%. *P<0.05.